Are opioid antagonists effective in attenuating the core symptoms of autism spectrum conditions in children: A systematic review

Journal of Intellectual Disability Research

Volumn 59, Issue 4, 2015, Pages 293-306

  Roy, A ^a,d   Roy, M ^b   Deb, S ^c,e   Unwin, G ^c  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b Birmingham Dental School   (United Kingdom)

^c UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^d University of Warwick and Coventry and Warwickshire Partnership NHS Trust   (United Kingdom)

^e IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Autism; Children; Hyperactivity; Intellectual disability; Naltrexone; Opioid antagonists

Indexed keywords

CARBAMAZEPINE; ENDORPHIN; NALTREXONE; OPIATE ANTAGONIST; PLACEBO; PROMAZINE; VALPROIC ACID; NARCOTIC ANTAGONIST;

ARTICLE; AUTISM; CLINICAL TRIAL (TOPIC); COMORBIDITY; DATA BASE; DATA EXTRACTION; DROWSINESS; EPILEPSY; HUMAN; HYPERACTIVITY; INTELLECTUAL IMPAIRMENT; IRRITABILITY; MEDICAL INFORMATION; RATING SCALE; RESTLESSNESS; SYSTEMATIC REVIEW; TREATMENT OUTCOME; WEIGHT REDUCTION; ADOLESCENT; AUTISM SPECTRUM DISORDER; CHILD; COMPLICATION; PRESCHOOL CHILD; PSYCHOMOTOR AGITATION; SELF-INJURIOUS BEHAVIOR;

ADOLESCENT; AUTISM SPECTRUM DISORDER; CHILD; CHILD, PRESCHOOL; HUMANS; NALTREXONE; NARCOTIC ANTAGONISTS; PSYCHOMOTOR AGITATION; SELF-INJURIOUS BEHAVIOR;

EID: 84924872472     PISSN: 09642633     EISSN: 13652788     Source Type: Journal    
DOI: 10.1111/jir.12122     Document Type: Article

References (41)

1. Abidin R. R. (1995) Parenting Stress Index. Psychological Assessment Resources, Odessa, FL.
2. Achenbach T. M. (1991) Manual for the Child Behaviour Checklist and 1991 Profile. University of Vermont Department of Psychiatry, Burlington.
3. Aman M. G., Singh N. N., Stewart A. W. & Field C. J. (1985) The Aberrant Behaviour Check list: a behaviour rating scale for the assessment of treatment effects. American Journal of Mental Deficiency 89, 485-491.
4. Anderson L. T., Campbell M., Grega D. M., Perry R., Small A. M. & Green W. H. (1984) Haloperidol in the treatment of infantile autism: effects on learning and behavioural symptoms. American Journal of Psychiatry 141, 1195-1202.
5. Autism and Developmental Disabilities Monitoring Network Surveillance (2012) Principle Investigators; Centres for Disease Control and Prevention. Prevalence of autism spectrum disorders-Autism and Developmental Disabilities Monitoring Network, 14 sites, United States, 2008. MMWR. Morbidity and Mortality Weekly Report 61, 1-19. Surveillance Summaries.
6. Baron-Cohen S., Scott F. J., Allison C., Williams J., Bolton P., Mathews F. E. etal. (2009) Prevalence of autism spectrum conditions: UK school based population study. British Journal of Psychiatry. 194, 500-509.
7. Barron J. L. & Sandman C. (1993) Pharmacological treatment. In: The handbook of Behaviour Therapy and Pharmacotherapy with Children: A comparative Analysis (eds V. B. Van Hasslet & M. Hersen ), pp. 129-147. Allyn and Bacon, Boston.
8. Barthelemy C., Adrien J. L., Tanguay P., Garreau B., Fermian J., Roux S. etal. (1990) The behavioural summarized evaluation: validity and reliability of a scale for the assessment of autistic behaviours. Journal of Autism and Developmental Disorders 20, 189-203.
9. Baumeister A. A. & Forehand R. (1973) Stereotyped acts. In: International Review of Research in Mental Retardation (ed. N. R. Ellis ), pp. 55-96. Academic Press, New York.
10. Bouvard M. P., Leboyer M., Luanay J., Recasens C., Plumet M., Waller-Perotte D. etal. (1995) Low dose naltrexone effects on plasma chemistries and clinical symptoms in autism: a double blind, placebo-controlled study. Psychiatry Research 58, 191-201.
11. Campbell M., Small A. M., Green W. H., Jennings S. J., Perry R., Bennett W. G. etal. (1984) Behavioural efficacy of haloperidol and lithium carbonate: a comparison of hospitalized aggressive children with conduct disorder. Archives of General Psychiatry 41, 650-656.
12. Campbell M., Adams P., Small A. M., Curren E. L., Overall J. E. & Anderson L. T. (1988) Efficacy and safety of fenfluramine in autistic children. Journal of the American Academy of Child and Adolescent Psychiatry 27, 434-439.
13. Campbell M., Anderson L. T., Small A. M., Locasio J. J. & Choroco M. C. (1990) Naltrexone in autistic children: a double-blind and placebo-controlled study. Psychopharmacology Bulletin 26, 130-135.
14. Campbell M., Anderson L. T., Small A. M., Adams P., Gonzalez N. M. & Ernst M. (1993) Naltrexone in autistic children: behavioural symptoms and attentional learning. Journal of the American Academy of Child and Adolescent Psychiatry 32, 1283-1291.
15. Campbell M., Aremnteros J. L., Malone R. P., Adams P. B., Eisenberg Z. W. & Overall J. E. (1997) Neuroleptic related dyskinesias in autistic children: a prospective longitudinal study. Journal of the American Academy of Child and Adolescent Psychiatry 36, 835-843.
16. Chamberlain R. S. & Herman B. H. (1990) A novel biochemical model linking dysfunctions in brain melatonin, propiomelanocortin peptides and serotonin in autism. Biological Psychiatry 28, 773-793.
17. Elbourne D. R., Altman D. G., Higgins J. P. T., Curtin F. & Worthington H. V. (2002) Meta analysis involving cross over trials: methodological issues. International Journal of Epidemiology 31, 140-149.
18. Elchaar G. M., Maisch N. M., Augusto L. M. & Wehring H. J. (2006) Efficacy and safety of naltrexone in paediatric patients with autistic disorder. Annals of Pharmacotherapy 40, 1086-1095.
19. Feldman H. M., Kolman B. K. & Gonzaga A. M. (1999) Naltrexone and communication skills in young children with autism. Journal of the American Academy of Child and Adolescent Psychiatry 38, 587-593.
20. Fish B. (1985) Children's Psychiatric Rating Scale. Psychopharmacology Bulletin 21, 753-764.
21. Gilliam J. E. (1995) Gilliam Autism Rating Scale. ProEd, Austin, TX.
22. Goyette C. H., Connors C. K. & Ulrich R. F. (1978) Normative data on revised Connors parent and teacher rating scales. Journal of Abnormal Child Psychology 6, 221-236.
23. Guy W. (ed.) (1976) Clinical global impressions. In: ECDEU Assessment Manual for Psychopharmacology, revised. National Institute of Mental Health, Rockville, MD.
24. Jadad R. R., Moore R. A., Carroll D., Jenjinson C., Reynolds D. J., Gavaghan D. J. etal. (1996) Assessing the quality of reports of randomised clinical trials: is blinding necessary? Controlled Clinical Trials 17, 1-12.
25. Kogan M. D., Blumberg S. J., Schieve L. A., Boyle C. A., Perrin J. M., Ghandour R. M. etal. (2009) Prevalence of parent reported diagnosis of autism spectrum disorder among children in the US, 2007. Pediatrics 125, 1395-1403.
26. Kolmen B. K., Feldman H. M., Handen B. L. & Janosky J. E. (1995) Naltrexone in young autistic children; a double blind placebo controlled crossover study. Journal of the American Academy of Child and Adolescent Psychiatry 34, 223-231.
27. Kolmen B. K., Feldman H. M., Handen B. L. & Janosky J. E. (1997) Naltrexone in young autistic children: replication study and learning measures. Journal of the American Academy of Child and Adolescent Psychiatry 36, 1570-1578.
28. Leboyer M., Bouvard M. P., Launay J., Tabuteau F., Waller D., Dogas M. etal. (1992) Brief report: a double blind study of naltrexone in infantile autism. Journal of Autism and Developmental Disorders 22, 309-319.
29. Matson J. L., Rotatori A. F. & Helsel W. J. (1985) Special feature: development of a rating scale to measure social skills in children: the Matson Evaluation of Social Skills with Youngsters (MESSY). Psychopharmacology Bulletin 21, 855-868.
30. Panksepp J. (1979) A neurochemical theory of autism. Trends in Neurosciences 2, 174-177.
31. Sandman C. A. (1988) Beta endorphin dysregulation in autistic and self injurious behaviour: a neurodevelopmental hypothesis. Synapse (New York, N.Y.) 2, 193-199.
32. Sandman C. A. & Hetrick W. P. (1995) Opiate mechanisms in self injury. Mental Retardation and Developmental Disabilities Research Reviews 1, 130-136.
33. Sandman C. A. & Kemp A. C. (2011) Opioid antagonists may reverse endogenous opiate 'dependence' in the treatment of self-injurious behavior. Pharmaceuticals 4, 366-381.
34. Schopler E., Reichler R. & Renner B. (1988) The Childhood Autism Rating Scale (CARS). Western Psychological Services, Los Angeles.
35. Schroeder S. R., Oster-Granite M. L. & Thompson T. (eds) (2002) Self-injurious Behavior: Gene-brain-behavior Relationships. American Psychological Association, Washington, DC.
36. Scifo R., Batticane N., Quattropani M. C., Spoto G. & Marchetti B. (1991) A double blind trial with naltrexone in autism. Brain Dysfunction 4, 301-307.
37. Symons F. J., Thompson T. & Rodriguez M. C. (2004) Self-injurious behaviour and the efficacy of naltrexone treatment: a quantitative synthesis. Mental Retardation and Developmental Research Reviews 10, 193-200.
38. Unwin G. L. & Deb S. (2011) Efficacy of atypical antipsychotic medication in the management of behaviour problems in children with intellectual disabilities and borderline intelligence: a systematic review. Research in Developmental Disabilities 32, 2121-2133.
39. Willemsen-Swinkels S. H. N., Buitelaar J. K., Weijnen F. G. & van Engeland H. (1995) Placebo controlled acute dosage naltrexone study in young autistic children. Psychiatry Research 58, 203-215.
40. Willemsen-Swinkels S. H. N., Buitelaar J. K. & van Engeland H. (1996) The effects of chronic naltrexone treatment in young autistic children: a double blind placebo controlled crossover study. Biological Psychiatry 39, 1023-1031.
41. Williams P. G., Allard A. M., Sears L., Dalrymple N. & Bloom A. S. (2001) Brief report: case reports on naltrexone use in children with autism: controlled observations regarding benefits and practical issues of medication management. Journal of Autism and Developmental Disorders 31, 103-108.